You’re exhausted even after eight hours of sleep. Your periods are irregular — or sometimes they just don’t show up at all. Your skin breaks out like you’re seventeen again, and no matter how carefully you eat, the weight creeps on around your belly and refuses to budge. You’ve Googled yourself into a spiral and stumbled across two terms that keep appearing together: PCOS and fatty liver disease.
Here’s something that might surprise you: these two conditions are deeply connected — and the thread that ties them together is a metabolic problem called insulin resistance. Understanding this link isn’t just academically interesting. It could fundamentally change how you approach your own health.

 

What Is PCOS, Really?

Polycystic ovary syndrome (PCOS) affects an estimated 8–13% of women of reproductive age worldwide, making it the most common endocrine disorder in this group.1 Despite its name, you don’t actually need to have cysts on your ovaries to be diagnosed with it. The Rotterdam criteria — the most widely used diagnostic framework — require at least two of three features: irregular or absent ovulation, elevated androgen levels (or symptoms of them, like excess hair growth and acne), and polycystic ovarian morphology on ultrasound.^II
What those diagnostic criteria don’t fully capture is how profoundly metabolic PCOS really is. For decades, it was classified primarily as a reproductive disorder. Today, science tells us a different story.

 

The Insulin Resistance Connection

At the heart of PCOS — in 65–80% of affected women — lies insulin resistance ^III. This means the body’s cells don’t respond normally to insulin, the hormone that signals cells to take up glucose from the blood. The pancreas compensates by pumping out more and more insulin, leading to chronically elevated insulin levels, also known as hyperinsulinemia.
This matters for the ovaries in a very specific way. Insulin directly stimulates the theca cells of the ovary to produce androgens: male sex hormones like testosterone ^IV. In a woman with insulin resistance, the ovaries are essentially being bombarded with a constant signal to overproduce testosterone. The result? Disrupted ovulation, irregular periods, acne, and hirsutism (excess body hair). It’s not a hormone problem that happens to affect metabolism, it’s a metabolic problem that derails hormones.
Insulin resistance in PCOS is partly driven by intrinsic defects in insulin signalling at the cellular level. Research has shown that women with PCOS have a unique post-receptor signalling defect. Specifically, excessive serine phosphorylation of the insulin receptor substrate, that impairs glucose uptake even in normal-weight women ^V. This means insulin resistance in PCOS isn’t always about excess body fat; it’s baked into the biology of the condition.

Enter the Liver

 

Now here’s where it gets really interesting. Your liver is one of the primary tissues that responds to insulin. When insulin resistance is present, the liver loses its ability to properly regulate fat metabolism. Instead of packaging and exporting fat efficiently, fat accumulates within liver cells, a condition called non-alcoholic fatty liver disease (NAFLD), now more accurately termed metabolic dysfunction-associated steatotic liver disease (MASLD) ^VI.
Women with PCOS have a significantly higher prevalence of NAFLD compared to women without PCOS, even after controlling for body mass index. A 2016 meta-analysis by Qu and colleagues found that PCOS was associated with a two-fold increased risk of NAFLD ^VII. More recently, a systematic review confirmed that this elevated risk persists across different ethnicities and body weight categories. Meaning, lean women with PCOS are still at elevated risk. ^VIII

What’s driving fat into the liver in PCOS? Several mechanisms:

• Hyperinsulinemia directly stimulates de novo lipogenesis — the liver essentially manufactures new fat from glucose. ^IX
• Elevated androgens promote visceral fat accumulation, which releases free fatty acids directly into the portal circulation that feeds the liver. ^X
• Dysbiosis of the gut microbiome, increasingly documented in PCOS, contributes to increased intestinal permeability and liver inflammation. ^XI

Recognising the Signs: When Both Are Present

 

The tricky thing about fatty liver disease is that it’s largely silent in its early stages. Most people don’t feel it. But when PCOS and fatty liver co-exist, there are patterns worth recognising:

Signs That May Indicate PCOS:

• Irregular menstrual cycles — fewer than 8 cycles per year, or cycles longer than 35 days
• Hirsutism — excess hair growth on the face, chin, chest, or abdomen
• Acne — particularly along the jawline and chin (a classic androgen-driven distribution)
• Thinning scalp hair (androgenic alopecia)
• Acanthosis nigricans — velvety, darkened skin in body folds like the neck and armpits, a hallmark of insulin resistance
• Difficulty losing weight, especially around the abdomen.
• Fatigue and brain fog, particularly after carbohydrate-heavy meals.
• Mood disturbances — women with PCOS have significantly higher rates of anxiety and depression. ^XII

Signs That May Indicate Fatty Liver:

• Upper right abdominal discomfort or heaviness (the liver sits here; not everyone experiences this)
• Persistent fatigue that doesn’t improve with rest
• Elevated liver enzymes on blood work (ALT and AST) — though enzymes can be normal even with fatty liver.
• Elevated triglycerides and low HDL cholesterol.
• Elevated fasting insulin or a HOMA-IR score above 2.5.
• Unexplained weight gain or difficulty losing weight.
• Bloating and digestive discomfort.

Many of these signs overlap significantly — which makes sense, because they share the same root cause.

The Vicious Cycle

 

Here’s what makes this metabolic duo so insidious: each condition can worsen the other. Fatty liver produces and releases pro-inflammatory cytokines, including TNF-α and IL-6, that further impair insulin signalling in peripheral tissues ^XIII. More inflammation → more insulin resistance → more androgen production → more visceral fat → more liver fat. It’s a self-reinforcing loop.
A landmark study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that women with PCOS and NAFLD had significantly worse insulin sensitivity and higher androgen levels than women with PCOS alone. This suggests that liver involvement amplifies the endocrine disruption of PCOS. ^XIV
Left unaddressed, fatty liver in PCOS can progress. MASLD exists on a spectrum: from simple steatosis (fat accumulation) → metabolic steatohepatitis (MASH, formerly NASH, with inflammation and liver cell damage) → fibrosis → cirrhosis. Studies suggest women with PCOS are more likely to have the more advanced, inflammatory form (MASH) rather than simple fat accumulation. ^XV

What the Science Says About Treatment

 

The good news is that insulin resistance, the shared root of both conditions, is genuinely modifiable. Here’s what has the strongest evidence:

1. Lifestyle Modification: The Non-Negotiable Foundation

A modest weight loss of 5–10% of body weight in women with PCOS who are overweight significantly improves menstrual regularity, reduces androgen levels, and improves insulin sensitivity ^XVI. In NAFLD, similar weight loss (particularly >7%) has been shown to reduce hepatic fat content by significant amounts and can even reverse early fibrosis. ^XVII
Diet quality matters more than macronutrient ratios. A 2019 randomised controlled trial found that a low-GI diet improved menstrual cyclicity and reduced markers of insulin resistance in PCOS more effectively than a conventional healthy diet. ^XVIII For liver health, the Mediterranean dietary pattern has the most robust evidence. It reduces hepatic fat, improves insulin sensitivity, and lowers cardiovascular risk. ^XIX

Key dietary strategies with evidence:

• Reduce ultra-processed foods and added sugars — fructose in particular drives de novo lipogenesis in the liver ^XX
• Increase fibre intake from vegetables, legumes and whole grains — fibre feeds beneficial gut bacteria that produce short-chain fatty acids, which improve insulin sensitivity.
• Prioritise anti-inflammatory fats — omega-3 fatty acids from oily fish reduce hepatic triglycerides and inflammation. ^XXI
• Time-restricted eating — emerging evidence suggests it can improve insulin sensitivity and reduce hepatic fat, though long-term RCT data in PCOS specifically are limited. ^XXII

Exercise is independently powerful. Both aerobic and resistance training improve insulin sensitivity through mechanisms that bypass the insulin receptor defect seen in PCOS. Muscle contractions activate GLUT4 transporters via an insulin-independent pathway. ^XXIII Which means, even if insulin signalling is deregulated, exercise may override that. A meta-analysis of exercise interventions in PCOS found that both types of training reduced fasting insulin and HOMA-IR. ^XXIV

2. Inositol Supplementation

Myo-inositol and D-chiro-inositol are naturally occurring compounds involved in insulin signalling. They’ve emerged as some of the most promising supplements for PCOS. A 2019 Cochrane-adjacent systematic review found that myo-inositol improved ovulation rates, reduced androgen levels, and improved insulin sensitivity in women with PCOS, with a favourable safety profile. ^XXV

For liver health specifically, inositol plays a role in lipid metabolism, and animal studies suggest benefits for hepatic steatosis, though human RCT data for liver outcomes in PCOS specifically are still limited. ^XXVI

3. Metformin

Metformin, an insulin sensitiser widely used in type 2 diabetes, has a decades-long track record in PCOS. It reduces insulin levels, modestly reduces androgen production, and can restore menstrual regularity. ^XXVII Interestingly, metformin also activates AMPK (AMP-activated protein kinase) in the liver, a key enzyme that promotes fat oxidation and inhibits fat synthesis — which may explain its modest but real benefit in NAFLD. ^XVIII

4. Optimising Gut Health

Emerging research is bringing the gut-liver axis into sharper focus. Dysbiosis in PCOS increases intestinal permeability (“leaky gut”), allowing bacterial products like lipopolysaccharide (LPS) to reach the liver via the portal vein, triggering inflammation.11 Probiotic supplementation has shown promising early results. A 12-week RCT found that Lactobacillus-based probiotics improved insulin resistance and reduced inflammatory markers in women with PCOS. ^XXIX

5. Addressing Sleep

This one is chronically underrated. Sleep disruption — including obstructive sleep apnoea (disproportionately common in PCOS)  independently worsens insulin resistance and promotes liver fat accumulation. ^XXX If you’re doing everything right and still not seeing results, a sleep study might be worth discussing with your doctor.

What to Ask Your Doctor

If you have PCOS, ask about:

• Baseline liver function tests (ALT, AST, GGT) and hepatic ultrasound to screen for fatty liver.
• Fasting insulin and HOMA-IR (not just fasting glucose. You can have normal glucose with high insulin for years before blood sugar tips over.
• Lipid panel: triglycerides and HDL are particularly relevant.
• HbA1c to assess average blood sugar over 3 months.
• Referral to a dietitian experienced in PCOS and metabolic health.

If fatty liver has been found, ask whether you should be referred to a hepatologist and what the degree of steatosis is. Knowing your baseline gives you something to measure improvement against.

The Bottom Line

 

PCOS and fatty liver disease are not two separate problems that happen to coincide. They are, in large part, two faces of the same underlying metabolic dysfunction. Insulin resistance sits at the centre of both, driving hormonal chaos in the ovaries while quietly loading fat into the liver.

The encouraging truth is that treating the root — improving insulin sensitivity through evidence-based lifestyle change, targeted supplementation, and where appropriate, medication — benefits both conditions simultaneously. You don’t need two separate treatment plans. You need one coherent strategy that addresses the metabolic core.

That’s not a small thing. It’s actually empowering.

References

 

1. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. PMID: 27664216

2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. PMID: 14711538

3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. PMID: 23065822

4. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83(6):2001–2005. PMID: 9626130

5. Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96(2):801–810. PMID: 7635975

6. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. PMID: 37363821

7. Qu Z, Zhu Y. Association between polycystic ovary syndrome and non-alcoholic fatty liver disease: a meta-analysis. Exp Ther Med. 2016;12(4):2500–2506. PMID: 27698750

8. Deng Y, Liu Z, Wang L, et al. Non-alcoholic fatty liver disease in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2021;43(1):151–159. PMID: 33896716

9. Lim JS, Mietus-Snyder M, Valente A, et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7(5):251–264. PMID: 20368739

10. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006;113(10):1148–1159. PMID: 16827826

11. Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502–1511. PMID: 29340590

12. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075–1091. PMID: 28333286

13. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008;14(3–4):222–231. PMID: 18235842

14. Tan S, Bechmann LP, Benson S, et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95(1):343–348. PMID: 19906812

15. Brzozowska MM, Ostapowicz G, Weltman M. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol. 2009;24(2):243–247. PMID: 19054265

16. Lim SS, Hutchison SK, Van Ryswyk E, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3:CD007506. PMID: 30921465

17. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378. PMID: 25865049

18. Marsh KA, Steinbeck KS, Atkinson FS, et al. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr. 2010;92(1):83–92. PMID: 20484445

19. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–846. PMID: 28545937

20. Stanhope KL. Sugar consumption, metabolic disease and obesity: the state of the controversy. Crit Rev Clin Lab Sci. 2016;53(1):52–67. PMID: 26376619

21. Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60(4):1211–1221. PMID: 25043514

22. Cienfuegos S, Gabel K, Kalam F, et al. Effects of 4- and 6-h time-restricted feeding on weight and cardiometabolic health: a randomized controlled trial in adults with obesity. Cell Metab. 2020;32(3):366–378. PMID: 32813017 and Xie W, Liao Q, Chen Y, et al. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. J Clin Endocrinol Metab. 2021;106(3):e1355–e1366. PMID: 33170263

23. Holloszy JO. Regulation by exercise of skeletal muscle content of mitochondria and GLUT4. J Physiol Pharmacol. 2008;59(Suppl 7):5–18. PMID: 19258654

24. Patten RK, Boyle RA, Moholdt T, et al. Exercise interventions in polycystic ovary syndrome: a systematic review and meta-analysis. Front Physiol. 2020;11:606. PMID: 32760280

25. Pundir J, Psaroudakis D, Savnur P, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018;125(3):299–308. PMID: 28544572

26. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811–1827. PMID: 23850516

27. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. PMID: 24151290

28. Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–156. PMID: 24393785

29. Ahmadi S, Jamilian M, Karamali M, et al. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017;20(4):254–261. PMID: 28427289

30. Theorell-Haglöw J, Berne C, Janson C, et al. Obstructive sleep apnoea is associated with decreased insulin sensitivity in females. Eur Respir J. 2008;31(5):1054–1060. PMID: 18184682